Follow Japan University News

Press releases 4 hits

Efficacy of Esophageal Cancer Postoperative Adjuvant Treatment, Peptide Vaccine Treatment, Elucidated 5-year Survival Rate Approx. Doubled for Esophageal Cancer Patients - Kindai University

Efficacy of Esophageal Cancer Postoperative Adjuvant Treatment, Peptide Vaccine Treatment, Elucidated 5-year Survival Rate Approx. Doubled for Esophageal Cancer Patients - Kindai University

Press releases   •   Sep 01, 2020 00:50 UTC

Kindai University’s Faculty of Medicine has, in a world first, shown the efficacy of cancer-specific vaccine therapy as a postoperative adjuvant therapy in a phase 2 clinical trial. Administration of cancer-specific vaccine therapy roughly doubled the 5-year survival rate of advanced esophageal cancer patients. Vaccine therapy amplifying CTL2 is expected to help validate peptide vaccine therapy.

Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University

Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University

Press releases   •   Jun 11, 2020 08:53 UTC

- Efficacy of molecular target drug Nivolumab verified in investigator-initiated clinical trial for use with CUP by hospital team from Kindai University’s Faculty of Medicine - Reductions by more than half in tumor size in over 20% of CUP patients observed - Nivolumab expected to become standard treatment for CUP cases with no standard treatment

Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University

Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University

Press releases   •   Nov 01, 2019 05:00 UTC

The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.

Ground Breaking Development of World’s First CurativeTreatment of Intractable Hepatocellular Carcinoma Path to Establishment of Standard Treatment of Hepatocellular Carcinoma - Kindai University

Press releases   •   Aug 05, 2019 02:00 UTC

Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.